 Connection
David Wyles to Coinfection
This is a "connection" page, showing publications David Wyles has written about Coinfection.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.123 |
|
|
|
-
Anthony DD, Sulkowski MS, Smeaton LM, Damjanovska S, Shive CL, Kowal CM, Cohen DE, Bhattacharya D, Alston-Smith BL, Balagopal A, Wyles DL. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. J Infect Dis. 2020 09 14; 222(8):1334-1344.
Score: 0.628
-
Wyles DL. Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease. Clin Liver Dis. 2019 08; 23(3):473-486.
Score: 0.574
-
Luetkemeyer AF, Wyles DL. CROI 2018: Highlights of Viral Hepatitis. Top Antivir Med. 2018 May; 26(1):30-38.
Score: 0.533
-
Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis. 2016 07 15; 63 Suppl 1:S3-S11.
Score: 0.471
-
Balagopal A, Smeaton LM, Quinn J, Venuto CS, Morse GD, Vu V, Alston-Smith B, Cohen DE, Santana-Bagur JL, Anthony DD, Sulkowski MS, Wyles DL, Talal AH. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. J Infect Dis. 2020 07 23; 222(4):601-610.
Score: 0.156
-
Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. Br J Clin Pharmacol. 2020 01; 86(1):132-142.
Score: 0.149
-
Wyles D, Br?u N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017 Jul 01; 65(1):6-12.
Score: 0.126
-
Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P. TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. J Infect Dis. 2017 02 15; 215(4):599-605.
Score: 0.123
-
Wyles DL. Regimens for Patients Coinfected with Human Immunodeficiency Virus. Clin Liver Dis. 2015 Nov; 19(4):689-706, vi-vii.
Score: 0.111
-
Luetkemeyer AF, Wyles DL. CROI 2015: Highlights of Viral Hepatitis Therapy. Top Antivir Med. 2015 Mar-Apr; 23(1):66-76.
Score: 0.107
-
Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018 09 14; 67(7):1010-1017.
Score: 0.034
-
Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Liver Int. 2017 12; 37(12):1796-1804.
Score: 0.031
-
Poveda E, Wyles D, Morano L, Pineda JA, Garc?a F. News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference. AIDS Rev. 2015 Oct-Dec; 17(4):231-7.
Score: 0.028
-
Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015 Mar 24-31; 313(12):1223-31.
Score: 0.027
-
Cachay ER, Hill L, Wyles D, Colwell B, Ballard C, Torriani F, Mathews WC. The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS One. 2014; 9(7):e102883.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|